Conclusions The initial safety profile of LY2090314 was established. MTD LY dose with pemetrexed/carboplatin is 40 mg IV every 3 weeks plus ranitidine. Efficacy of LY plus pemetrexed/carboplatin requires confirmation in randomized trials. (Source: Investigational New Drugs)
from MedWorm: Mesothelioma http://www.medworm.com/index.php?rid=151404984&cid=c_409_13_f&fid=33392&url=http%3A%2F%2Flink.springer.com%2F10.1007%2Fs10637-015-0278-7
A first-in-human phase I dose-escalation, pharmacokinetic, and pharmacodynamic evaluation of intravenous LY2090314, a glycogen synthase kinase 3 inhibitor, administered in combination with pemetrexed and carboplatin
ad
Enregistrer un commentaire